Eight percent weight loss, halved liver fat, lower triglycerides, and reduced appetite cannot be explained by GIP alone
Studies suggest that GIP may enhance the tolerability of GLP-1 therapies, particularly by reducing gastrointestinal side effects
A disproportionality analysis (Godfrey et al., JEADV 2025) found a reporting odds ratio of 1.73 for tirzepatide (95% CI: 1.42 to 2.09), and as high as 2.46 for semaglutide
Apps can provide users with information on healthy lifestyles, proper nutrition, and the benefits of regular intermittent fasting
These chemicals wind up inside your body in a variety of ways: 1 We Breathe Them In Americans spend approximately 90% of their time indoors
This suggests that Ex-4 mediates its protective effects through a GLP-1-R-SIRT1-p53 signaling axis [41]